Adrenergic-receptor polymorphisms and heart failure

New England Journal of Medicine

Volumn 347, Issue 15, 2002, Pages 1196-1199

  Hajjar, Roger J ^a   MacRae, Calum A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR;

ADRENERGIC SYSTEM; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; EDITORIAL; GENETIC POLYMORPHISM; HEART FAILURE; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; RISK FACTOR; SIGNAL TRANSDUCTION; SYMPATHETIC TONE;

AFRICAN CONTINENTAL ANCESTRY GROUP; HEART FAILURE, CONGESTIVE; HUMANS; NOREPINEPHRINE; POLYMORPHISM, GENETIC; RECEPTORS, ADRENERGIC; RECEPTORS, ADRENERGIC, ALPHA-2; RECEPTORS, ADRENERGIC, BETA-1; SIGNAL TRANSDUCTION;

EID: 0037057592     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMe020105     Document Type: Editorial

References (15)

1. Dec GW, Fuster V. Idiopathic dilated cardiomyopathy. N Engl J Med 1994;331:1564-75.
2. Dries DL, Exner DV, Gersh BJ, Cooper HA, Carson PE, Domanski MJ. Racial differences in the outcome of left ventricular dysfunction. N Engl J Med 1999;340:609-16. [Erratum, N Engl J Med 1999;341:298.]
3. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-7.
4. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55.
5. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13.
6. Exner DV, Dries DL, Domanski MJ, Cohn JN. Lesser response to angiotensin-converting-enzyme therapy therapy in black as compared with white patients with left ventricular dysfuction. N Engl J Med 2001;344:1351-7.
7. Wagoner LE, Craft LL, Singh B, et al. Polymorphisms of the beta(2)adrenergic receptor determine exercise capacity in patients with heart failure. Circ Res 2000;86:834-40.
8. Liggett SB, Wagoner LE, Craft LL, et al. The Ile164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. J Clin Invest 1998;102:1534-9.
9. 2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med 2002;347:1135-42.
10. Brede M, Wiesmann F, Jahns R, et al. Feedback inhibition of catecholamine release by two different a2-adrenoreceptor subtypes prevents progression of heart failure. Circulation (in press).
11. Engelhardt S, Hein L, Wiesmann F, Lohse MJ. Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. Proc Natl Acad Sci U S A 1999;96:7059-64.
12. Rockman HA, Koch WJ, Lefkowitz RJ. Seven-transmembrane-spanning receptors and heart function. Nature 2002;415:206-12.
13. The Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001;344:1659-67.
14. Cardon LR, Bell JI. Association study designs for complex diseases. Nat Rev Genet 2001;2:91-9.
15. Current human genome assembly at National Center for Biotechnology Information: Homo sapiens genome view. Bethesda, Md.: National Center for Biotechnology Information, 2002. (Accessed September 20, 2002, at http://wwww.ncbi.nlm.nih.gov/cgi-bin/Entrez/map_search?=hum.inf&query.